Literature DB >> 22765392

Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea.

D J Gracie1, J S Kane, S Mumtaz, A F Scarsbrook, F U Chowdhury, A C Ford.   

Abstract

BACKGROUND: Many physicians do not consider the diagnosis of bile acid malabsorption in patients with chronic diarrhea, or do not have access to testing. We examined yield of 23-seleno-25-homo-tauro-cholic acid (SeHCAT) scanning in chronic diarrhea patients, and attempted to identify predictors of a positive test.
METHODS: Consecutive patients with chronic diarrhea undergoing SeHCAT scan over a 7-year period were identified retrospectively. Bile acid malabsorption was defined as present at a retention of <15%. Medical records were reviewed to obtain information regarding proposed risk factors. Gastrointestinal symptoms were recorded, and patients were classified as having diarrhea-predominant irritable bowel syndrome (IBS-D) if they reported abdominal pain or discomfort. Independent risk factors were assessed using multivariate logistic regression, and odds ratios (ORs) with 99% confidence intervals (CIs) were calculated. KEY
RESULTS: Of 373 patients, 190 (50.9%) had bile acid malabsorption. Previous cholecystectomy (OR 2.51; 99% CI 1.10-5.77), terminal ileal resection or right hemicolectomy for Crohn's disease (OR 12.4; 99% CI 2.42-63.8), and terminal ileal resection or right hemicolectomy for other reasons (OR 7.94; 99% CI 1.02-61.6) were associated with its presence. Seventy-seven patients had IBS-D, and 21 (27.3%) tested positive. There were 168 patients with no risk factors for a positive SeHCAT scan, other than chronic diarrhea, and 63 (37.5%) had bile acid malabsorption. CONCLUSIONS &amp; INFERENCES: Bile acid malabsorption was present in 50% of patients undergoing SeHCAT scanning. Almost 40% of those without risk factors had evidence of bile acid malabsorption, and in those meeting criteria for IBS-D prevalence was almost 30%.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22765392     DOI: 10.1111/j.1365-2982.2012.01953.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  23 in total

Review 1.  Complete Mesocolic Excision and D3 Lymphadenectomy versus Conventional Colectomy for Colon Cancer: A Systematic Review and Meta-Analysis.

Authors:  Tamara Díaz-Vico; María Fernández-Hevia; Aida Suárez-Sánchez; Carmen García-Gutiérrez; Luka Mihic-Góngora; Daniel Fernández-Martínez; José Antonio Álvarez-Pérez; Jorge Luis Otero-Díez; José Electo Granero-Trancón; Luis Joaquín García-Flórez
Journal:  Ann Surg Oncol       Date:  2021-06-04       Impact factor: 5.344

2.  What is irritable bowel syndrome?

Authors:  Peter J Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

4.  Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation.

Authors:  Ruchit Sood; Michael Camilleri; David J Gracie; Matthew J Gold; Natalie To; Graham R Law; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2016-08-02       Impact factor: 10.864

Review 5.  Advances in understanding of bile acid diarrhea.

Authors:  Michael Camilleri
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-11-25       Impact factor: 3.869

6.  Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.

Authors:  Ian M Johnston; Jonathan D Nolan; Sanjeev S Pattni; Richard N Appleby; Justine H Zhang; Sarah L Kennie; Gaganjit K Madhan; Sina Jameie-Oskooei; Shivani Pathmasrirengam; Jeremy Lin; Albert Hong; Peter H Dixon; Catherine Williamson; Julian R F Walters
Journal:  Am J Gastroenterol       Date:  2016-02-09       Impact factor: 10.864

7.  Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.

Authors:  A Shiotani; H Kusunoki; M Ishii; H Imamura; N Manabe; T Kamada; J Hata; J L Merchant; K Haruma
Journal:  Neurogastroenterol Motil       Date:  2014-11-27       Impact factor: 3.598

Review 8.  Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment.

Authors:  Alan N Barkun; Jonathan Love; Michael Gould; Henryk Pluta; Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

Review 9.  Chronic diarrhoea following surgery for colon cancer-frequency, causes and treatment options.

Authors:  Jonathan Yde; Helene M Larsen; Søren Laurberg; Klaus Krogh; Hanne B Moeller
Journal:  Int J Colorectal Dis       Date:  2018-03-27       Impact factor: 2.571

10.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.